Nader Sanai
13
5
10
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
7.7%
1 terminated/withdrawn out of 13 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
100%
1 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
Role: lead
Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas
Role: lead
Abemaciclib in Newly Diagnosed Meningioma Patients
Role: lead
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Role: lead
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Role: lead
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
Role: lead
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
Role: lead
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
Role: lead
Infigratinib in Recurrent High-Grade Glioma Patients
Role: lead
Clinical Trial of BMS-986504 in Recurrent GBM Patients
Role: lead
Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma
Role: lead
Study of Pamiparib in Newly Diagnosed and rGBM
Role: lead
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Role: lead
All 13 trials loaded